Results from the “IBS in America” national survey conducted by the American Gastroenterological Association (AGA) demonstrates the need for improved communication, diagnosis and management of IBS
Entera Health, Inc. today celebrates the role of the AGA in commissioning the “IBS in America” national survey of over 3000 IBS sufferers, both diagnosed and undiagnosed, and 302 physicians who treat IBS patients. The AGA claims it as the most comprehensive IBS survey ever conducted of patients and physicians, examining the complexities around becoming diagnosed with IBS, the physical and emotional impact of the condition, and patient satisfaction with current treatment modalities. Results of the survey were released on December 14, 2015.
Some important insights from the survey include:
- IBS is estimated to impact nearly 35 million Americans and is the 7th most common diagnosis among primary care physicians.
- IBS causes recurring abdominal pain and constipation or diarrhea, along with a variety of other symptoms, and significantly impacts patients’ daily lives in many ways.
- 75% of respondents reported feeling frustrated and/or depressed, and their symptoms had a significant impact on their productivity and performance.
- Overall, three-quarters of those with IBS symptoms tried OTC products before they spoke to a health-care professional about symptoms, reporting that they tried an average of 3.6 OTC products. A majority report taking OTC meds for a year or less before consulting a doctor.
- The most common recommendations from HCPs for treating IBS symptoms included changes to diet (65%), probiotics or other supplements (39%), or exercise (33%); less than 25% of patients reported being “very satisfied” with these treatments.
It is worth noting that EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) is the sole prescription brand specifically mentioned in the IBS-D Treatment and Satisfaction section of the survey, posting some impressive patient satisfaction results. The “IBS in America” national survey was sponsored by Ironwood Pharmaceuticals, Inc. and Allergan plc. To learn more, please view the survey results.
About Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome (IBS) is a complex and commonly diagnosed gastrointestinal disorder, characterized by recurrent abdominal pain or discomfort associated with altered bowel habits that negatively affects patients’ daily activities and quality of life. Population-based studies indicate that the worldwide prevalence of IBS is approximately 9% to 22%. Symptoms may include abnormal stool form or frequency, defecation straining, bloating, urgency, feelings of incomplete bowel movement, and passing mucus. It is further categorized based upon stool consistency leading to a diagnosis of IBS with either constipation (IBS-C), diarrhea (IBS-D), mixed with alternating constipation and diarrhea (IBS-M) or undefined (IBS-U) which may have symptoms of bloating and distention. Unfortunately, most therapies that are currently used to manage patients with IBS are aimed at lessening symptoms rather than the underlying cause of the disorder, which has led to an increased interest in multi-modal therapeutic approaches aimed at restoring intestinal health and nutritional status for these patients.
EnteraGam® (serum-derived bovine immunoglobulin isolate, SBI) is a prescription medical food product intended to provide for distinctive nutritional requirements that are unique for the clinical dietary management of specific intestinal disorders [e.g., in irritable bowel syndrome with diarrhea (IBS-D), inflammatory bowel disease (IBD), and HIV-associated enteropathy]. EnteraGam®, as a medical food, must be used under physician supervision.
Important Safety Information
EnteraGam® contains beef protein; therefore, patients who have an allergy to beef or any component of EnteraGam® should not take this product. The most commonly reported adverse events in clinical studies (incidence of 2%-5%) include mild nausea, constipation, stomach cramps, headache, and increased urination. EnteraGam® has not been studied in pregnant or nursing women, so the choice to administer EnteraGam® for patients who are pregnant or nursing is at the clinical discretion of the prescribing physician. EnteraGam® does not contain any milk products such as lactose, casein, or whey. It is gluten-free, dye-free, and soy-free. EnteraGam® contains 5 g of SBI and other ingredients such as dextrose (5 g) and trace amounts of sunflower lecithin. For full prescribing information, visit the product website at http://enteragam.com/.
About Entera Health, Inc.
Entera Health, Inc. is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs. The staff’s passion is to help people thrive through healthier living. The staff’s motivation for conducting basic research, clinical studies, and appropriately educating patients and healthcare providers is driven to meet this goal. Learn more at http://www.enterahealth.com/.
For questions, please contact:
Aage Lauridsen, Chief Executive Officer